Limits...
Galectin-4 serves as a prognostic biomarker for the early recurrence / metastasis of hepatocellular carcinoma.

Cai Z, Zeng Y, Xu B, Gao Y, Wang S, Zeng J, Chen L, Huang A, Liu X, Liu J - Cancer Sci. (2014)

Bottom Line: Galectin-4 is a multifunctional lectin found at both intracellular and extracellular sites.Here we report that galectin-4 was significantly downregulated in early recurrent/metastatic HCC patients, when compared to non-recurrent/metastatic HCC patients.Combined with clinicopathological features, the higher serologic level of galectin-4 was well associated with more aggressive characteristics of HCC.

View Article: PubMed Central - PubMed

Affiliation: Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China; The Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China.

Show MeSH

Related in: MedlinePlus

Galectin-4 is significantly downregulated in early recurrent/metastatic hepatocellular carcinoma (HCC). (a) Quantitative PCR analysis of galectin-4 expression in three HCC patient groups with different recurrence/metastasis time. (b) Western blot analysis of galectin-4 expression in three HCC patient groups with different recurrence/metastasis time. (c) Different galectin-4 expression levels in HCC tumor tissues and peri-tumor tissues. Galectin-4 expression was semiquantitatively categorized into four groups: (a) negative (0), (b) weak (1+), (c) moderate (2+), and (d) strong (3+). Original magnification of 20×. *P < 0.05; **P < 0.01; ***P < 0.001. NR/M, patients with no recurrence/metastasis within 2 years of hepatectomy; R/M≤12 months, patients with recurrence/metastasis within 12 months of hepatectomy; R/M12–24 months, patients with recurrence/metastasis within 12–24 months of hepatectomy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4462376&req=5

fig01: Galectin-4 is significantly downregulated in early recurrent/metastatic hepatocellular carcinoma (HCC). (a) Quantitative PCR analysis of galectin-4 expression in three HCC patient groups with different recurrence/metastasis time. (b) Western blot analysis of galectin-4 expression in three HCC patient groups with different recurrence/metastasis time. (c) Different galectin-4 expression levels in HCC tumor tissues and peri-tumor tissues. Galectin-4 expression was semiquantitatively categorized into four groups: (a) negative (0), (b) weak (1+), (c) moderate (2+), and (d) strong (3+). Original magnification of 20×. *P < 0.05; **P < 0.01; ***P < 0.001. NR/M, patients with no recurrence/metastasis within 2 years of hepatectomy; R/M≤12 months, patients with recurrence/metastasis within 12 months of hepatectomy; R/M12–24 months, patients with recurrence/metastasis within 12–24 months of hepatectomy.

Mentions: In a previous study, we applied the iTRAQ-based quantitative proteomic approach (iTRAQ-2DLC-MS/MS) to identify potential diagnostic biomarkers for the early recurrence/metastasis of HCC.(18) From that analysis, we identified an interesting protein, galectin-4, that was significantly downregulated in early recurrent/metastatic HCC tumors. To further evaluate the prognostic potential of galectin-4 in HCC patients, we assessed its expression in three HCC patient groups with different recurrence/metastasis times by q-PCR. As shown in Figure 1(a), the q-PCR analysis revealed that galectin-4 expression was downregulated 7.83-fold in the early recurrence/metastasis group (R/M≤12 months, n = 9, P = 0.002) and 2.51-fold in the late recurrence/metastasis group (R/M12–24 months, n = 9, P = 0.042) compared with the NR/M group (n = 9). To further confirm galectin-4 expression at the protein level, additional Western blot analysis was carried out. As shown in Figure 1(b), galectin-4 levels were significantly higher in the NR/M group compared to both the R/M≤12 months group and the R/M12–24 months group at the protein level. Overall, these results clearly indicated that galectin-4 expression was significantly decreased at both the mRNA and the protein level in recurrent/metastatic HCC tumors, especially in HCC tumors with early recurrence/metastasis.


Galectin-4 serves as a prognostic biomarker for the early recurrence / metastasis of hepatocellular carcinoma.

Cai Z, Zeng Y, Xu B, Gao Y, Wang S, Zeng J, Chen L, Huang A, Liu X, Liu J - Cancer Sci. (2014)

Galectin-4 is significantly downregulated in early recurrent/metastatic hepatocellular carcinoma (HCC). (a) Quantitative PCR analysis of galectin-4 expression in three HCC patient groups with different recurrence/metastasis time. (b) Western blot analysis of galectin-4 expression in three HCC patient groups with different recurrence/metastasis time. (c) Different galectin-4 expression levels in HCC tumor tissues and peri-tumor tissues. Galectin-4 expression was semiquantitatively categorized into four groups: (a) negative (0), (b) weak (1+), (c) moderate (2+), and (d) strong (3+). Original magnification of 20×. *P < 0.05; **P < 0.01; ***P < 0.001. NR/M, patients with no recurrence/metastasis within 2 years of hepatectomy; R/M≤12 months, patients with recurrence/metastasis within 12 months of hepatectomy; R/M12–24 months, patients with recurrence/metastasis within 12–24 months of hepatectomy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4462376&req=5

fig01: Galectin-4 is significantly downregulated in early recurrent/metastatic hepatocellular carcinoma (HCC). (a) Quantitative PCR analysis of galectin-4 expression in three HCC patient groups with different recurrence/metastasis time. (b) Western blot analysis of galectin-4 expression in three HCC patient groups with different recurrence/metastasis time. (c) Different galectin-4 expression levels in HCC tumor tissues and peri-tumor tissues. Galectin-4 expression was semiquantitatively categorized into four groups: (a) negative (0), (b) weak (1+), (c) moderate (2+), and (d) strong (3+). Original magnification of 20×. *P < 0.05; **P < 0.01; ***P < 0.001. NR/M, patients with no recurrence/metastasis within 2 years of hepatectomy; R/M≤12 months, patients with recurrence/metastasis within 12 months of hepatectomy; R/M12–24 months, patients with recurrence/metastasis within 12–24 months of hepatectomy.
Mentions: In a previous study, we applied the iTRAQ-based quantitative proteomic approach (iTRAQ-2DLC-MS/MS) to identify potential diagnostic biomarkers for the early recurrence/metastasis of HCC.(18) From that analysis, we identified an interesting protein, galectin-4, that was significantly downregulated in early recurrent/metastatic HCC tumors. To further evaluate the prognostic potential of galectin-4 in HCC patients, we assessed its expression in three HCC patient groups with different recurrence/metastasis times by q-PCR. As shown in Figure 1(a), the q-PCR analysis revealed that galectin-4 expression was downregulated 7.83-fold in the early recurrence/metastasis group (R/M≤12 months, n = 9, P = 0.002) and 2.51-fold in the late recurrence/metastasis group (R/M12–24 months, n = 9, P = 0.042) compared with the NR/M group (n = 9). To further confirm galectin-4 expression at the protein level, additional Western blot analysis was carried out. As shown in Figure 1(b), galectin-4 levels were significantly higher in the NR/M group compared to both the R/M≤12 months group and the R/M12–24 months group at the protein level. Overall, these results clearly indicated that galectin-4 expression was significantly decreased at both the mRNA and the protein level in recurrent/metastatic HCC tumors, especially in HCC tumors with early recurrence/metastasis.

Bottom Line: Galectin-4 is a multifunctional lectin found at both intracellular and extracellular sites.Here we report that galectin-4 was significantly downregulated in early recurrent/metastatic HCC patients, when compared to non-recurrent/metastatic HCC patients.Combined with clinicopathological features, the higher serologic level of galectin-4 was well associated with more aggressive characteristics of HCC.

View Article: PubMed Central - PubMed

Affiliation: Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China; The Liver Center of Fujian Province, Fujian Medical University, Fuzhou, China.

Show MeSH
Related in: MedlinePlus